In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative (DNDi) and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. This continued ‘fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.
See DNDi press release
"In 1975–99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011 (...)"
READ THE ARTICLE
To cite this content :
Jean-Hervé Bradol, Deadly Gaps Persist in New Drug Development for Neglected Diseases, 30 October 2013, URL : https://www.msf-crash.org/en/publications/medicine-and-public-health/deadly-gaps-persist-new-drug-development-neglected-diseases
If you want to criticize or develop this content, you can find us on twitter or directly on our site.Contribute